ArticleEuropean journal of nuclear medicine and molecular imaging2021
A prospective intra-individual comparison of [
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Diagnostic accuracy ofJapanese journal of radiology · 2026Article
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
- The role of positron emission tomography in the evaluation and management of musculoskeletal lesions-a narrative review.Annals of joint · 2025Review
- Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.Biomedicines · 2024Review
- Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy.International journal of molecular sciences · 2023Review
- Article
- Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Observational
- The Role of PET/CT in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- A Retrospective Comparative Study of Sodium Fluoride NaLife (Basel, Switzerland) · 2022Article
- An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Preclinical evaluation and first in human study of AlFrontiers in oncology · 2022Article
- Imaging dysregulated calcium homeostasis in acute myocardial infarction with [European journal of nuclear medicine and molecular imaging · 2021Article
- Global experience with PSMA-based alpha therapy in prostate cancer.European journal of nuclear medicine and molecular imaging · 2021Review
- Pattern of Prostate Cancer Recurrence Assessed byJournal of clinical medicine · 2021Article
- [Bioconjugate chemistry · 2021Article
- Article
- Preparation and Biological Evaluation of [Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate cancer (PCa) commonly metastasizes to the bones. There are several radionuclide techniques for imaging PCa skeletal metastases. We aimed to compare the lesion detection rate of [
methodsWe prospectively recruited two cohorts of patients (staging and re-staging cohorts) with advanced prostate cancer. The staging cohort was treatment-naïve PCa patients who showed skeletal metastases on bone scan. These patients were subsequently imaged with [
resultsEighteen patients were included with a median age of 68 years (range = 48-80) and a median Gleason score of 8. There were ten patients in the staging cohort with a median PSA of 119.26 ng/mL (range = 4.63-18,948.00) and eight patients in the re-staging cohort with a median PSA of 48.56 ng/mL (range = 6.51-3175.00). In the staging cohort, skeletal metastases detected by [
conclusionIn patients with advanced prostate cancer, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.